Press releases

PREDICt-RM collaborative study between Boston Scientific, American College of Cardiology and Yale University highlights improved outcomes in ICD and CRT-D patients followed with the LATITUDE™ System.

Boston Scientific Shockless Implant Evaluation (SIMPLE) study results presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th annual scientific sessions.

Advanced Illumina™ 3D Programming Software provides highly significant pain relief in study patients.

Innovative technology designed to treat intrauterine fibroids and polyps.

Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions.

Broad set of data reinforces commitment to advancing research and technology in electrophysiology.

Promising clinical data to be presented at annual conference.

Boston Scientific will participate in the healthcare conference on May 13, 2014. Learn how to watch the webcast or replay.

Advanced drug-eluting stent system recently received Japan Ministry of Health, Labor and Welfare approval.

Company exceeds earnings per share guidance on the strength of continued revenue growth.

Clinical trial is designed to establish the safety and effectiveness of both lead families.

Event will be held in San Francisco, site of the Heart Rhythm Society 35th Annual Scientific Sessions.

Newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

Study to evaluate clinical outcomes and economic value of the Vercise™ Deep Brain Stimulation (DBS) System.

The first implant of the S-ICD System performed in Hong Kong.

Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...

Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...

MADIT-CRT long-term follow-up results presented at the American College of Cardiology and published in the New England Journal of Medicine.

Includes late breaking clinical trial assessing use of the Boston Scientific CRT-D therapy in patients with mild heart failure

Recognition is for delivering world class results and demonstrating a strong culture of operational excellence at Maple Grove, Minnesota manufacturing facility.

First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes.

Newest bare metal stent technology features advanced architecture and provides physicians with enhanced treatment option for patients

Appointment fills a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from eleven to twelve.